<a href="https://www.fiercebiotech.com/biotech/ox40-drug-inhibrx-mooted-ma-target-tops-keytruda-early-look-midphase-data" hreflang="en">Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data </a>
fiercebiotech.com·May 11, 2026
Inhibrx Biosciences' OX40 agonist combined with Keytruda significantly increased response rates in a midphase clinical trial, prompting the biotech to move forward with the program, which has garnered interest from Merck & Co.
The most valuable insight for you is that Inhibrx Biosciences' success in doubling the response rate by combining their OX40 agonist with Keytruda in a midphase clinical trial presents a potential investment opportunity or partnership interest, particularly as it has already piqued the interest of Merck & Co. This indicates a promising development in immunotherapy that could impact the biotech landscape and warrants monitoring for further advancements or collaborations.